CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT
IND APPROVAL OF ICF004 AS A CLASS 1 NEW DRUG BY THE NMPA

This announcement is made by CF PharmTech, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the latest research and development of the Group.

INTRODUCTION

The board (the **"Board"**) of directors (the **"Directors"**) of the Company is pleased to announce that the investigational new drug ("**IND**") application for ICF004, a Class 1 new drug (the **"Product"**), was recently approved by the National Medical Products Administration of the People's Republic of China (the **"NMPA"**).

The Product is intended for the treatment of interstitial lung disease (ILD), a disease area that includes indications such as idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

ILD is characterized by progressive worsening of respiratory symptoms and irreversible decline in lung function, resulting in poor prognosis. While oral therapies have been approved, published clinical and real-world data suggest that existing treatments, although capable of slowing lung function decline to a degree, remain associated with limited survival benefit, adverse reaction burden and treatment discontinuation. A global unmet clinical need persists for therapies that achieve a more favorable balance among efficacy, safety and long-term treatment adherence.

With a potential global first-in-class mechanism, the Product adopts an inhaled dry powder delivery route designed to deliver the drug directly to lung lesion areas. Preclinical studies of the Product indicated (i) a differentiated distribution between pulmonary tissue exposure and systemic blood exposure following inhaled administration, and (ii) an observed anti-fibrotic activity in preclinical models with a favorable safety profile. These findings provide research support for the development strategy of enhancing target organ exposure through localized targeted delivery while reducing systemic exposure. However, preclinical results are preliminary and their translation to human safety and efficacy remains to be verified in clinical trials.

STRATEGIC SIGNIFICANCE

The IND approval of the Product marks the entry of the Group's inhaled innovative drug candidate into the clinical development stage, a key milestone with long-term strategic implications. This milestone validates the Group's capability to integrate complex formulations, delivery systems and device engineering with unmet clinical needs and to advance innovative drug candidates into clinical development, establishing a replicable research and development paradigm for subsequent innovative projects across respiratory and other therapeutic areas.

The Group will maintain active communication with the NMPA and advance the clinical development of the Product in compliance with regulatory requirements, including clinical trial initiation, subject enrollment and staged data readouts.

RISK WARNING

The IND approval of the Product represents a preliminary stage in the clinical development and regulatory process. The Product is subject to further review and assessment by the NMPA, and the Company cannot guarantee the successful development or commercialization of the Product. Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Given such risks and uncertainties, **shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities – from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms – the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening global presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, June 1, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.